Cipla has received two fresh notices from the Government demanding a total of Rs 73 crore for alleged over-pricing on two drugs. The notices, from the National Pharmaceutical Pricing Authority (NPPA), demanded Rs 47.70 crore for respiratory drug Salbutamol and Rs 25.46 crore for antibiotic Ciprofloxacin.
Cipla has been litigating over the NPPA's notices on five of its drugs, including the aforementioned two, for about 10 years now. And the over-charge amount claimed by the Government from Cipla has crossed Rs 1,000 crore. The other drugs from Cipla under the scanner for alleged over-charging include respiratory drug Theophylline, cephalosporin-antibiotic Cefadroxil and antibiotic Norfloxacin.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: